Satellos Bioscience Inc. (NASDAQ:MSLE) Given Consensus Rating of “Moderate Buy” by Analysts

Satellos Bioscience Inc. (NASDAQ:MSLE) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $18.00.

Several research firms recently commented on MSLE. Wall Street Zen upgraded Satellos Bioscience from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Canaccord Genuity Group upgraded Satellos Bioscience to a “moderate buy” rating in a research note on Thursday, May 21st. Zacks Research raised Satellos Bioscience to a “hold” rating in a report on Tuesday, February 10th. Leerink Partners started coverage on Satellos Bioscience in a research note on Monday, April 6th. They set an “outperform” rating and a $20.00 price objective on the stock. Finally, Cantor Fitzgerald started coverage on Satellos Bioscience in a research note on Wednesday, March 11th. They set an “overweight” rating on the stock.

Satellos Bioscience Stock Performance

NASDAQ:MSLE opened at $7.30 on Tuesday. Satellos Bioscience has a one year low of $4.53 and a one year high of $13.39. The stock has a 50-day simple moving average of $7.05. The firm has a market capitalization of $152.06 million, a PE ratio of -4.56 and a beta of 1.60.

Satellos Bioscience (NASDAQ:MSLE) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.02). As a group, equities research analysts expect that Satellos Bioscience will post -2.26 EPS for the current fiscal year.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.